Clinical trial • Phase I • Endocrinology
LY4057996 for Type 1 diabetes | Type 2 diabetes | Healthy volunteer
Phase I trial of LY4057996 for Type 1 diabetes | Type 2 diabetes | Healthy volunteer. 132 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 1 diabetes | Type 2 diabetes | Healthy volunteer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 10-02-2025
- First CTIS Authorization Date
- 24-04-2025
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 132
Recruitment
- Planned Sample Size
- 132
- Recruitment Window Months
- 16
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 132
Germany
- Earliest CTIS Part Ii Submission Date
- 14-04-2025
- Latest Decision Or Authorization Date
- 20-03-2026
- Processing Time Days
- 340
- Number Of Sites
- 1
- Number Of Participants
- 132
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Oliver Klein
- Contact Person Email
- oliver.klein@profil.com
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- LY4057996
Related trials
Other published trials that may interest you.